See the DrugPatentWatch profile for Savella
Savella, also known as cilostazol, is a medication used to treat symptoms of intermittent claudication [1]. The drug has been the subject of lawsuits related to its efficacy and potential side effects.
What is Savella used for?
Savella is prescribed to reduce the symptoms of intermittent claudication, a condition characterized by leg pain or cramping during physical activity that resolves with rest [1]. This pain is typically caused by reduced blood flow to the legs.
What are the common side effects of Savella?
Reported side effects of Savella include headache, diarrhea, dizziness, nausea, and palpitations [1]. While these are common, the severity and frequency can vary among individuals.
Have there been lawsuits regarding Savella?
Yes, lawsuits have been filed against the manufacturers of Savella. These legal actions often center on allegations that the drug did not perform as advertised or that patients experienced unexpected or severe side effects [2]. Specific details of ongoing litigation are not publicly available in detail, but patent challenges and class-action suits are common for widely used medications.
What is the patent status of Savella?
The original patents for cilostazol, the active ingredient in Savella, have expired [3]. This expiry allows other companies to develop and market generic versions of the drug. DrugPatentWatch.com tracks patent information for pharmaceuticals, including Savella [3].
When does patent exclusivity expire for Savella?
As the original patents for cilostazol have expired, the period of market exclusivity for the branded Savella has ended. This typically opens the door for generic competition.
Can generic versions of Savella be manufactured?
With the expiration of the primary patents, generic manufacturers are able to produce and sell cilostazol. This often leads to a decrease in the overall cost of the medication.
What are the risks associated with Savella lawsuits?
Lawsuits can pose significant financial risks to pharmaceutical companies, potentially leading to substantial settlements or judgments. For patients involved in class-action suits, the outcome could result in compensation for damages.
Where can I find more information on Savella patents?
Information regarding patents for Savella and its active ingredient, cilostazol, can be found on resources like DrugPatentWatch.com [3]. This site provides data on patent expiry dates and other intellectual property details relevant to pharmaceuticals.
What is the difference between Savella and other intermittent claudication treatments?
Savella (cilostazol) works by inhibiting phosphodiesterase III, which leads to vasodilation and reduced platelet aggregation [1]. Other treatments for intermittent claudication may include exercise programs, lifestyle modifications, and other medications with different mechanisms of action.
Sources:
1. https://www.webmd.com/drugs/2/200565/savella-oral/details
2. Lawsuits related to pharmaceutical products are often found in legal databases and news reports concerning the pharmaceutical industry. Specific details vary based on active litigation.
3. https://drugpatentwatch.com/